Related Experiment Video
Updated: Nov 26, 2025
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I
Emma Koehorst1, Alfonsina Ballester-Lopez1,2, Virginia Arechavala-Gomeza3,4
1Neuromuscular and Neuropediatric Research Group, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Campus Can Ruti, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
Abstract:
MicroRNAs (miRNAs) are mostly known for their gene regulation properties, but they also play an important role in intercellular signaling. This means that they can be found in bodily fluids, giving them excellent biomarker potential. Myotonic Dystrophy type I (DM1) is the most frequent autosomal dominant muscle dystrophy in adults, with an estimated prevalence of 1:8000. DM1 symptoms include muscle weakness, myotonia, respiratory failure, cardiac conduction defects, cataracts, and endocrine disturbances. Patients display heterogeneity in both age of onset and disease manifestation. No treatment or cure currently exists for DM1, which shows the necessity for a biomarker that can predict disease progression, providing the opportunity to implement preventative measures before symptoms arise. In the past two decades, extensive research has been conducted in the miRNA expression profiles of DM1 patients and their biomarker potential. Here we review the current state of the field with a tissue-specific focus, given the multi-systemic nature of DM1 and the intracellular signaling role of miRNAs.
Insights
MicroRNAs (miRNAs) show promise as biomarkers for Myotonic Dystrophy type I (DM1), a genetic muscle disorder. Research explores miRNA expression in bodily fluids to predict DM1 progression and enable early intervention.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- MicroRNAs (miRNAs) are key regulators of gene expression and function in intercellular signaling.
- Found in bodily fluids, miRNAs possess significant potential as diagnostic biomarkers.
- Myotonic Dystrophy type I (DM1) is a prevalent autosomal dominant muscle dystrophy affecting adults, characterized by diverse symptoms and variable onset.
Purpose of the Study:
- To review the current research on microRNA expression profiles in Myotonic Dystrophy type I (DM1) patients.
- To evaluate the biomarker potential of miRNAs for predicting DM1 disease progression.
- To highlight the tissue-specific focus in miRNA research due to DM1's multi-systemic nature.
Main Methods:
- Review of existing scientific literature on miRNA expression in DM1.
- Analysis of studies focusing on miRNA detection in bodily fluids of DM1 patients.
- Examination of the role of miRNAs in intercellular signaling within the context of DM1.
Main Results:
- Extensive research over two decades has identified specific miRNA expression profiles associated with DM1.
- miRNAs detected in bodily fluids demonstrate potential for non-invasive DM1 diagnosis and prognosis.
- Tissue-specific miRNA analysis is crucial for understanding DM1's complex pathology.
Conclusions:
- MicroRNAs represent a promising avenue for developing predictive biomarkers for Myotonic Dystrophy type I.
- Further research into tissue-specific miRNA profiles could lead to early detection and personalized management strategies for DM1.
- The utilization of miRNAs as biomarkers may facilitate preventative measures before the onset of severe DM1 symptoms.
More Related Videos
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
10:28Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
Published on: April 3, 2021
